NCT06447103View on ClinicalTrials.gov

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

December 1, 2029

Study Completion Date

December 1, 2030

Conditions
Clear Cell Renal Cell CarcinomaSarcomatoid Renal Cell CarcinomaStage II Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Computed Tomography

Undergo CT, PET/CT, and CT of the brain

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI of the brain

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Zirconium Zr 89 Girentuximab

Given IV

Trial Locations (1)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT06447103 - An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | Biotech Hunter | Biotech Hunter